Masonic Cancer Center, University of Minnesota
cancer.umn.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
286
Active
48
Phase 3
12
Total enrollment
16,258
Pipeline matrix
Showing 40 of 98 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cyclophosphamide | — | — | 68 | ||||
| Fludarabine | — | — | 37 | ||||
| Melphalan | — | — | 19 | ||||
| Busulfan | — | — | 25 | ||||
| mycophenolate mofetil | — | — | 22 | ||||
| Tacrolimus | — | — | — | 8 | |||
| Rituximab | — | — | — | — | 10 | ||
| etoposide | — | — | 13 | ||||
| Thymoglobulin | — | — | — | — | — | 4 | |
| Cell | — | — | — | — | — | 2 | |
| Total Body Irradiation | — | — | — | — | — | 2 | |
| G-CSF | — | — | — | 6 | |||
| Alemtuzumab | — | — | — | — | 5 | ||
| Stem Cell Transplantation | — | — | — | — | 2 | ||
| Sirolimus | — | — | — | 5 | |||
| bortezomib | — | — | — | — | 7 | ||
| cytarabine | — | — | — | — | — | 6 | |
| carmustine | — | — | — | — | — | 5 | |
| IL-2 | — | — | — | — | 5 | ||
| Granulocyte colony-stimulating factor | — | — | — | — | 2 | ||
| Lenalidomide | — | — | — | — | — | 2 | |
| Levetiracetam | — | — | — | — | — | 2 | |
| Stem cell | — | — | — | — | — | 2 | |
| KYMRIAH | — | — | — | — | — | 1 | |
| YESCARTA | — | — | — | — | — | 1 | |
| Fludarabine 30mg/m2 4 doses | — | — | — | — | — | 1 | |
| Cyclophosphamide 500 mg/m2; 2 doses | — | — | — | — | — | 1 | |
| Fludarabine 30mg/m2 3 doses | — | — | — | — | — | 1 | |
| Cyclophosphamide 500 mg/m2; 3 doses | — | — | — | — | — | 1 | |
| Fludarabine 25mg/m2 3 days | — | — | — | — | — | 1 | |
| Cyclophosphamide 250 mg/m2; 3 days | — | — | — | — | — | 1 | |
| Tecartus | — | — | — | — | — | 1 | |
| Abecma, Intravenous Suspension | — | — | — | — | — | 1 | |
| Cyclophosphamide 900 mg/m2; 1 day | — | — | — | — | — | 1 | |
| Breyanzi Injectable Product | — | — | — | — | — | 1 | |
| AdaptNK | — | — | — | — | — | 1 | |
| Rabbit ATG | — | — | — | — | — | 1 | |
| Post-Transplant G-CSF | — | — | — | — | — | 1 | |
| Bupivacaine | — | — | — | — | — | 1 | |
| Hydromorphone | — | — | — | — | — | 1 |
58 more active programs hidden
Next readouts
- 2020-06-23
- 2023-11-03
- 2024-02-09
- 2024-05-31
- 2025-08-01
- 2025-10-28
- 2025-12-30
- 2026-01-05
- 2026-03-26
- 2026-09
Top conditions
- Leukemia30
- Lymphoma27
- Myelodysplastic Syndromes24
- Ovarian Cancer24
- Acute Myeloid Leukemia22
- Breast Cancer21
- Multiple Myeloma19
- Lung Cancer14
Frequently asked questions about Masonic Cancer Center, University of Minnesota
- How many clinical trials does Masonic Cancer Center, University of Minnesota have on ClinicalTrials.gov?
- Masonic Cancer Center, University of Minnesota is listed as the lead sponsor on 286 clinical trials in ClinicalTrials.gov, 48 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Masonic Cancer Center, University of Minnesota's trials are in Phase 3?
- 12 of Masonic Cancer Center, University of Minnesota's trials are in Phase 3, spread across 98 active drug programs.
- What therapeutic areas does Masonic Cancer Center, University of Minnesota focus on?
- Masonic Cancer Center, University of Minnesota's most-studied conditions on ClinicalTrials.gov are Leukemia, Lymphoma, Myelodysplastic Syndromes, Ovarian Cancer, Acute Myeloid Leukemia.
- When are Masonic Cancer Center, University of Minnesota's next clinical trial readouts?
- Masonic Cancer Center, University of Minnesota has 10 upcoming primary-completion readouts tracked here; the soonest is “Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy”, expected around 2020-06-23.